TRYPTOPHAN CONCENTRATIONS INCREASE IN CEREBROSPINAL-FLUID AND BLOOD AFTER ZIDOVUDINE TREATMENT IN PATIENTS WITH HIV TYPE-1 INFECTION

被引:35
作者
GISSLEN, M
LARSSON, M
NORKRANS, G
FUCHS, D
WACHTER, H
HAGBERG, L
机构
[1] GOTHENBURG UNIV, DEPT CLIN NEUROSCI, GOTHENBURG, SWEDEN
[2] UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA
关键词
D O I
10.1089/aid.1994.10.947
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cerebrospinal fluid (CSF) and blood concentrations of indoleamines and catecholamines were analyzed in 14 HIV-1-seropositive individuals before antiviral treatment,vith zidovudine, after 3-14 months of treatment, and, in 8 of the patients, also after 14-30 months. The median pretreatment concentrations of tryptophan in CSF and blood were low (224 ng/ml and 6.0 mu g/ml, respectively), but an increase in these values by an average of 40% in CSF and 23% in blood was seen after 3-14 months of zidovudine treatment (p < 0.01) and remained undiminished after 14-30 months of treatment. No significant change was observed in the 5-hydroxytryptamine (5-HT, serotonin) level in blood or in the CSF concentrations of the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) and the dopamine metabolite homovanillic acid (HVA). The CSF concentrations of the noradrenalin metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) had decreased by 12% on average (p < 0.01) by the time of the second follow-up, that is, after 14-30 months of zidovudine treatment. A decrease in neopterin during antiretroviral treatment correlated with an increase in tryptophan (p < 0.01). The data suggest that an association between decreased immune stimulation and reduced tryptophan degradation in patients treated with zidovudine.
引用
收藏
页码:947 / 951
页数:5
相关论文
共 29 条
[1]   NEURONAL CELL KILLING BY THE ENVELOPE PROTEIN OF HIV AND ITS PREVENTION BY VASOACTIVE INTESTINAL PEPTIDE [J].
BRENNEMAN, DE ;
WESTBROOK, GL ;
FITZGERALD, SP ;
ENNIST, DL ;
ELKINS, KL ;
RUFF, MR ;
PERT, CB .
NATURE, 1988, 335 (6191) :639-642
[2]   CEREBROSPINAL-FLUID NEOPTERIN IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BREW, BJ ;
BHALLA, RB ;
PAUL, M ;
GALLARDO, H ;
MCARTHUR, JC ;
SCHWARTZ, MK ;
PRICE, RW .
ANNALS OF NEUROLOGY, 1990, 28 (04) :556-560
[3]  
BREY RL, 1991, J ACQ IMMUN DEF SYND, V4, P435
[4]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IS PRESENT IN THE CEREBROSPINAL-FLUID OF A MAJORITY OF INFECTED INDIVIDUALS [J].
CHIODI, F ;
KEYS, B ;
ALBERT, J ;
HAGBERG, L ;
LUNDEBERG, J ;
UHLEN, M ;
FENYO, EM ;
NORKRANS, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (07) :1768-1771
[5]   HUMAN IMMUNODEFICIENCY VIRUS-INFECTION OF THE BRAIN .1. VIRUS ISOLATION AND DETECTION OF HIV SPECIFIC ANTIBODIES IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH VARYING CLINICAL CONDITIONS [J].
CHIODI, F ;
SONNERBORG, A ;
ALBERT, J ;
GAINES, H ;
NORKRANS, G ;
HAGBERG, L ;
ASJO, B ;
STRANNEGARD, O ;
FENYO, EM .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1988, 85 (03) :245-257
[6]   THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
SCHOOLEY, RT ;
JACKSON, GG ;
DURACK, DT ;
KING, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191
[7]  
FUCHS D, 1990, J ACQ IMMUN DEF SYND, V3, P873
[8]   NEOPTERIN CONCENTRATIONS IN CEREBROSPINAL-FLUID AND SERUM OF INDIVIDUALS INFECTED WITH HIV-1 [J].
FUCHS, D ;
CHIODI, F ;
ALBERT, J ;
ASJO, B ;
HAGBERG, L ;
HAUSEN, A ;
NORKRANS, G ;
REIBNEGGER, G ;
WERNER, ER ;
WACHTER, H .
AIDS, 1989, 3 (05) :285-288
[9]   IMMUNE ACTIVATION AND DECREASED TRYPTOPHAN IN PATIENTS WITH HIV-1 INFECTION [J].
FUCHS, D ;
FORSMAN, A ;
HAGBERG, L ;
LARSSON, M ;
NORKRANS, G ;
REIBNEGGER, G ;
WERNER, ER ;
WACHTER, H .
JOURNAL OF INTERFERON RESEARCH, 1990, 10 (06) :599-603
[10]  
FUCHS D, 1989, J ACQ IMMUN DEF SYND, V2, P158